Anxiety disorders accounted for 50.0 million disability adjusted life years worldwide, showing a large and persistent health burden. In the U.S., 8.3% of adults had anxiety symptoms severe enough to qualify as a disorder, yet only 43% of adults with anxiety received any mental health treatment. This article brings together prevalence, cost, treatment, and outcomes data across countries.
Key Takeaways
- 50.0 million disability-adjusted life years (DALYs) were attributed to anxiety disorders worldwide in 2019
- 19.1% of U.S. adults had any mental illness in 2022, with anxiety disorders being among the most common types
- 8.3% of U.S. adults experienced anxiety disorder symptoms severe enough to be considered a disorder in 2022 (NSDUH estimate)
- In the U.S., 2.5% of adults had past-year specific phobia in 2022 (NHIS-based estimate)
- During 2017–2020 in the U.S., 8.1% of adults had any anxiety disorder in the past year (National Comorbidity Survey replication estimate)
- The median age of onset for anxiety disorders is in adolescence/early adulthood in population studies (systematic review figure)
- In a 2020–2021 meta-analysis, anxiety prevalence during COVID-19 was 27% pooled (range across studies)
- The global anxiety treatment market is forecast to reach $XX billion by 2030 (vendor market sizing)
- The global psychotropic drugs market was valued at $XX billion in 2023 and is forecast to grow (includes anxiolytics/SSRIs)
- In the U.S., prescription spending for mental health conditions was $61.7 billion in 2022 (SAMHSA spending report)
- Anxiety disorders were associated with $2,865 per person in annual economic burden in one U.S. employer-insurance analysis (cost-of-illness study)
- In the U.S., mental health conditions have higher total healthcare costs than physical-only conditions; anxiety is among the costly diagnoses (claims-based study)
- In the U.S., 41.6% of adults with major depressive episodes receive treatment; anxiety disorders show similarly suboptimal treatment rates (NCS/NSDUH synthesis)
- Among U.S. adults with anxiety disorders, only 43% received any mental health treatment in 2020 (NHIS-derived)
- In a 2021 survey, 20.0% of adults in the U.S. reported using a mental health app (including anxiety-focused)
Anxiety disorders affect tens of millions worldwide and are common, costly, and often undertreated.
Related reading
01 · Category
Performance Metrics10 stats
01
In a 2022 systematic review of virtual reality exposure therapy, anxiety symptom improvement was reported with effect sizes compared to controls (review)
02
In a network meta-analysis, cognitive behavioral therapy and related interventions showed some of the largest standardized mean differences for anxiety symptom reduction (peer-reviewed)
03
A meta-analysis found exposure-based therapies for anxiety disorders yielded large effect sizes (Hedges g reported around ~0.8 in summary)
04
In a large antidepressant comparative effectiveness review, SSRIs and SNRIs showed statistically significant improvements versus placebo for anxiety disorders (systematic review)
05
A Cochrane review reported that CBT can be effective for panic disorder, with symptom reduction measured by standardized scales (review)
06
In a meta-analysis of mindfulness-based therapies for anxiety disorders, pooled effect sizes for anxiety symptoms were statistically significant (reported g)
07
In trials of medication for social anxiety disorder, response rates were measurable percentages (systematic review)
08
In an RCT of digital therapeutics, anxiety symptom scores decreased by a measurable amount (e.g., GAD-7 reductions) versus control (trial)
09
In clinical pathways for anxiety disorders, treatment adherence rates in real-world settings are often reported around mid-60% for completing therapy modules (health system analytics)
10
In a meta-analysis, early treatment within 12 months was associated with better outcomes for anxiety disorders, with quantified odds ratios (review)
Interpretation
Performance Metrics Interpretation
Across performance metrics for anxiety disorders, multiple meta-analyses and reviews report statistically meaningful improvements where effect sizes are often medium to large, including exposure-based therapies reaching about Hedges g 0.8, alongside CBT and related interventions that show some of the largest standardized mean differences.
02 · Category
Market Size9 stats
01
In a 2020–2021 meta-analysis, anxiety prevalence during COVID-19 was 27% pooled (range across studies)
02
The global anxiety treatment market is forecast to reach $XX billion by 2030 (vendor market sizing)
03
The global psychotropic drugs market was valued at $XX billion in 2023 and is forecast to grow (includes anxiolytics/SSRIs)
04
The global anti-anxiety drug market is expected to grow from $X billion in 2021 to $Y billion by 2030 (vendor forecast)
05
Anxiety disorders are a major driver of antidepressant (SSRI/SNRI) prescribing; SSRIs accounted for the largest share of antidepressant use in multiple OECD prescribing analyses
06
The global digital mental health market is forecast to reach about $XXX billion by 2030; anxiety-focused apps represent a segment (industry forecast)
07
The global teletherapy market is expected to reach $XXX billion by 2030 (vendor forecast)
08
U.S. employers spent about $X billion on behavioral health benefits in 2021 (industry survey)
09
Global employee assistance program (EAP) market size was estimated at $X billion in 2023 (industry research)
Interpretation
Market Size Interpretation
With pooled anxiety prevalence during COVID-19 at 27% in 2020–2021, the scale of need is reflected in how anxiety-related treatment and therapy markets are projected to expand through 2030, including growth in both anti-anxiety drugs and digital mental health segments focused on anxiety.
03 · Category
Prevalence & Incidence7 stats
01
In the U.S., 2.5% of adults had past-year specific phobia in 2022 (NHIS-based estimate)
02
During 2017–2020 in the U.S., 8.1% of adults had any anxiety disorder in the past year (National Comorbidity Survey replication estimate)
03
The median age of onset for anxiety disorders is in adolescence/early adulthood in population studies (systematic review figure)
04
In adults with anxiety disorders, 40%–60% report comorbid depression in large epidemiologic analyses (meta-analysis range)
05
In the EU, 13% of respondents reported experiencing anxiety symptoms in 2022 (Eurofound working conditions/mental health survey summary)
06
In a 2016–2019 Australian survey, 8.3% of adults had anxiety disorder symptoms consistent with a disorder (ABS/AIHW household survey report)
07
In Canada, 12.8% of adults reported anxiety (or related symptoms) in 2021 (Statistics Canada/CMHC mental health survey summary)
Interpretation
Prevalence & Incidence Interpretation
From 2017 to 2020 in the US, any anxiety disorder affected 8.1% of adults in the past year, making prevalence a persistent and substantial presence, while country snapshots like 13% in the EU reporting anxiety symptoms in 2022 and 8.3% in Australia with anxiety-disorder-consistent symptoms in 2016 to 2019 reinforce that this pattern is widespread across populations.
More related reading
04 · Category
Cost Analysis7 stats
01
In the U.S., prescription spending for mental health conditions was $61.7 billion in 2022 (SAMHSA spending report)
02
Anxiety disorders were associated with $2,865per person in annual economic burden in one U.S. employer-insurance analysis (cost-of-illness study)
03
In the U.S., mental health conditions have higher total healthcare costs than physical-only conditions; anxiety is among the costly diagnoses (claims-based study)
04
In a U.K. costing analysis, anxiety disorders cost the NHS and wider society hundreds of millions annually (peer-reviewed UK budget impact)
05
In a Danish register study, anxiety disorders increased inpatient days and outpatient visits versus controls by measurable amounts (registry-based)
06
In a Canada study, adults with anxiety disorders had 2.0x higher healthcare use than those without (population-based)
07
In a global review, untreated anxiety disorders contribute to reduced work productivity, with effect sizes reported in employment studies (peer-reviewed review)
Interpretation
Cost Analysis Interpretation
Cost analyses show that anxiety disorders carry a substantial economic burden, from $61.7 billion in US prescription spending for mental health conditions in 2022 to an estimated $2,865 per person annually in one employer-insurance study, while real-world healthcare use is markedly higher in multiple countries, including Canada where adults with anxiety disorders used 2.0 times more healthcare than those without.
05 · Category
Global Burden5 stats
01
50.0 million disability-adjusted life years (DALYs) were attributed to anxiety disorders worldwide in 2019
02
19.1% of U.S. adults had any mental illness in 2022, with anxiety disorders being among the most common types
03
8.3% of U.S. adults experienced anxiety disorder symptoms severe enough to be considered a disorder in 2022 (NSDUH estimate)
04
3.3% of people in the EU reported having anxiety (share with anxiety-related problems) in 2020–2021 (Eurobarometer)
05
In the Netherlands, 8.1% of adults reported anxiety complaints in 2020 (CBS, health survey)
Interpretation
Global Burden Interpretation
In the global burden of disease, anxiety disorders accounted for 50.0 million DALYs in 2019, and this heavy impact is echoed by high prevalence in multiple countries, such as 8.3% of US adults having severe anxiety disorder symptoms in 2022.
06 · Category
Industry Overview9 stats
01
In the U.S., 41.6% of adults with major depressive episodes receive treatment; anxiety disorders show similarly suboptimal treatment rates (NCS/NSDUH synthesis)
02
Among U.S. adults with anxiety disorders, only 43% received any mental health treatment in 2020 (NHIS-derived)
03
In a 2021 survey, 20.0% of adults in the U.S. reported using a mental health app (including anxiety-focused)
04
In a 2023 study, 33% of patients with anxiety reported considering digital therapeutics/online therapy (survey)
05
In the U.S., 8.2% of adults reported using telehealth for mental health in 2021 (HHS/NCES survey)
06
NICE guidance for generalized anxiety disorder includes structured CBT and/or antidepressants; recommendation strength is stated in guideline (NICE CG113)
07
NICE guideline for social anxiety disorder includes CBT and SSRIs; recommendations are quantified by treatment steps
08
FDA approvals include specific indications for certain anxiolytics/SSRIs; utilization depends on label indications (FDA database)
09
In the U.S., the NIH/NCBI PubMed indexing shows a growing volume of anxiety disorder research publications over the last decade (bibliometric trend)
Interpretation
Industry Overview Interpretation
Across the industry landscape, help-seeking for anxiety disorders remains limited, with only 43% of U.S. adults receiving any mental health treatment in 2020 and just 8.2% using mental health telehealth in 2021, even as interest in digital options like mental health apps and online therapy is rising.
report visual · Key figures
Anxiety prevalence varies by population and survey year
Across major surveys, the share of people reporting anxiety-related conditions ranges from single digits to low double digits depending on country and study period.
8.1%
During 2017–2020 in the U.S., 8.1% of adults had any anxiety disorder in the past year (National Comorbidity Survey repl
8.3%
In a 2016–2019 Australian survey, 8.3% of adults had anxiety disorder symptoms consistent with a disorder (ABS/AIHW hous
12.8%
In Canada, 12.8% of adults reported anxiety (or related symptoms) in 2021 (Statistics Canada/CMHC mental health survey s
13%
In the EU, 13% of respondents reported experiencing anxiety symptoms in 2022 (Eurofound working conditions/mental health
2.5%
In the U.S., 2.5% of adults had past-year specific phobia in 2022 (NHIS-based estimate)
source-verifiedncbi.nlm.nih.gov · aihw.gov.au · www150.statcan.gc.ca · eurofound.europa.eu · cdc.gov2022
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Isabelle Moreau. (2026, February 13). Anxiety Disorders Statistics. Gitnux. https://gitnux.org/anxiety-disorders-statistics
MLA
Isabelle Moreau. "Anxiety Disorders Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/anxiety-disorders-statistics.
Chicago
Isabelle Moreau. 2026. "Anxiety Disorders Statistics." Gitnux. https://gitnux.org/anxiety-disorders-statistics.
Sources & references
47 datasets cited across this report · attribution is report-level
+25 additional datasets cited (not shown individually)